Abrdn Life Sciences Investors (NYSE:HQL) Sees Significant Decline in Short Interest

Abrdn Life Sciences Investors (NYSE:HQL) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 33,800 shares, a drop of 54.4% from the November 15th total of 74,100 shares. Based on an average trading volume of 75,400 shares, the short-interest ratio is currently 0.4 days.

Abrdn Life Sciences Investors Stock Down 1.0 %

Shares of HQL traded down $0.14 during midday trading on Friday, hitting $13.84. 73,123 shares of the company traded hands, compared to its average volume of 92,054. The firm has a 50 day moving average of $14.58 and a 200-day moving average of $14.71. Abrdn Life Sciences Investors has a 52 week low of $12.76 and a 52 week high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 10th. Investors of record on Thursday, November 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Thursday, November 21st. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. This represents a $2.00 dividend on an annualized basis and a yield of 14.45%.

Institutional Trading of Abrdn Life Sciences Investors

A number of large investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its holdings in shares of Abrdn Life Sciences Investors by 2.6% in the second quarter. Commonwealth Equity Services LLC now owns 33,788 shares of the company’s stock valued at $479,000 after purchasing an additional 868 shares in the last quarter. Stephens Inc. AR lifted its position in Abrdn Life Sciences Investors by 7.6% during the third quarter. Stephens Inc. AR now owns 12,707 shares of the company’s stock valued at $192,000 after purchasing an additional 896 shares during the last quarter. Wedbush Securities Inc. grew its stake in shares of Abrdn Life Sciences Investors by 8.2% in the 2nd quarter. Wedbush Securities Inc. now owns 16,673 shares of the company’s stock worth $236,000 after buying an additional 1,261 shares in the last quarter. Sanctuary Advisors LLC increased its holdings in shares of Abrdn Life Sciences Investors by 11.4% in the 3rd quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock worth $183,000 after buying an additional 1,355 shares during the last quarter. Finally, Future Financial Wealth Managment LLC bought a new stake in shares of Abrdn Life Sciences Investors in the 3rd quarter worth about $30,000. Institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.